Trk (TrkB) receptor antagonists - Pipeline Insight, 2024

Trk (TrkB) receptor antagonists - Pipeline Insight, 2024

DelveInsight’s, “Trk (TrkB) receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Trk (TrkB) receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Trk (TrkB) receptor antagonists Understanding

Trk (TrkB) receptor antagonists: Overview

Trk receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. Trk receptors affect neuronal survival and differentiation through several signaling cascades. However, the activation of these receptors also has significant effects on functional properties of neurons.

Function –TrkB has the highest affinity to the binding of brain-derived neurotrophic factor (BDNF) and NT-4. BDNF is a growth factor that has important roles in the survival and function of neurons in the central nervous system. The binding of BDNF to TrkB receptor causes many intracellular cascades to be activated, which regulate neuronal development and plasticity, long-term potentiation, and apoptosis. Although both BDNF and NT-4 have high specificity to TrkB, they are not interchangeable.[13] In a mouse model study where BDNF expression was replaced by NT-4, the mouse with NT4 expression appeared to be smaller and exhibited decreased fertility. Recently, studies have also indicated that TrkB receptor is associated with Alzheimer's disease.

Trk (TrkB) receptor antagonistss- KRAS mutations occur in multiple types of cancer, and Trk (TrkB) receptor antagonistss are pancancer therapies that work against tumors anywhere in the body. An effective and well-tolerated targeted agent against KRAS is expected to have a significant impact and will be a radical breakthrough in clinical oncology. In various research, KRAS p.G12C small-molecule inhibitors are emerging as an effective treatment option for metastatic disease.

Trk (TrkB) receptor antagonists Emerging Drugs Chapters

This segment of the Trk (TrkB) receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Trk (TrkB) receptor antagonists Emerging Drugs

• Repotrectinib (TPX-0005): Turning Point Therapeutics

Repotrectinib is a small (low molecular weight), macrocyclic tyrosine kinase inhibitor of ROS1, TRK and ALK. Repotrectinib was designed to efficiently bind with the active kinase conformation and avoid steric interference from a variety of clinically resistant mutations. The compact and rigid three-dimensional structure enables repotrectinib to precisely and efficiently bind deep into the ATP binding pocket of the kinase, and potentially circumvent the steric interference that results in resistance to bulkier kinase inhibitors, especially the solvent-front and gatekeeper mutations of ROS1, TRK and ALK kinases. It is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for both TKI-naïve and TKI-pretreated patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors.

Further product details are provided in the report……..

Trk (TrkB) receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Trk (TrkB) receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Trk (TrkB) receptor antagonists

There are approx. 5+ key companies which are developing the Trk (TrkB) receptor antagonists. The companies which have their Trk (TrkB) receptor antagonists drug candidates in the mid stage, i.e. phase 1/2 include, Turning Point Therapeutics.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Trk (TrkB) receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Trk (TrkB) receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Trk (TrkB) receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Trk (TrkB) receptor antagonists drugs.

Report Highlights

• In the coming years, the Trk (TrkB) receptor antagonists market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Trk (TrkB) receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• There are several companies involved in developing therapies for Trk (TrkB) receptor antagonists . Launch of emerging therapies of Trk (TrkB) receptor antagonists will significantly impact the market.
• A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Trk (TrkB) receptor antagonists .
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Trk (TrkB) receptor antagonists ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Trk (TrkB) receptor antagonists Report Insights

• Trk (TrkB) receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Trk (TrkB) receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Trk (TrkB) receptor antagonists drugs?
• How many Trk (TrkB) receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Trk (TrkB) receptor antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Trk (TrkB) receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Trk (TrkB) receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Turning Point Therapeutics

Key Products

• Repotrectinib (TPX-0005)